Clinical pharmacology of timentin (ticarcillin and clavulanic acid).
Ticarcillin (4 gm) and clavulanic acid (0.1 gm) were simultaneously administered as timentin to patients with cancer as therapy for infections. The pharmacokinetics of both ticarcillin and clavulanic acid were studied in 15 patients after 30-minute and 2-hour intravenous infusions. The mean (+/- SD) ticarcillin plasma peak concentrations after the two infusions were 341 +/- 76 and 210 +/- 60 micrograms/ml. The plasma terminal t1/2 values of ticarcillin were 80 +/- 32 and 56 +/- 12 minutes. The AUCs were 631 +/- 189 and 601 +/- 230 mg/L X hr. The volumes of distribution of the area were 15 +/- 5 and 21 +/- 7 L and total clearances were 115 +/- 36 and 127 +/- 54 ml/min. The corresponding values for clavulanic acid after the infusions are as follows: mean peak concentrations, 5 +/- 1 and 4 +/- 1 micrograms/ml; plasma terminal t1/2 values, 84 +/- 24 and 74 +/- 36 minutes; AUCs, 11 +/- 3 and 11 +/- 6 mg/L X hr; volumes of distribution of the area, 22 +/- 3 and 32 +/- 6 L; and total clearances, 170 +/- 58 and 175 +/- 68 ml/min.
D000328:Adult; D000368:Aged; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000097:blood*; D004338:Drug Combinations / Q000008:administration & dosage / Q000097:blood; D005260:Female; D006801:Humans; D007239:Infections / Q000188:drug therapy; D007263:Infusions, Parenteral; D007700:Kinetics; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010406:Penicillins / Q000097:blood*; D013982:Ticarcillin / Q000008:administration & dosage / Q000097:blood*
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin